A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063 · X-TOLE2 Phase 3Completed
- Lead sponsor
- Xenon Pharmaceuticals Inc. (Industry)
- Enrollment
- 380 (actual)
- Start date
- 18 Nov 2022
- Primary completion
- 12 Jan 2026 (actual)
- Study completion
- 3 Feb 2026
- Last update posted
- 14 May 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 3
Interventions
- XEN1101 Drug
- Placebo Drug
Conditions and primary outcome
- Focal Onset Seizures
Primary outcome
Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo. (From baseline through to the double blind period (week 12))
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05614063.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05614063 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.